Latest News

Breaking Barriers: VelaVigo's Second US Partnership Signals Booming China-US Biotech Collaborations

Breaking Barriers: VelaVigo’s Second US Partnership Signals Booming China-US Biotech Collaborations

Frank Dolan April 18, 2025

VelaVigo's Bold Move: How Chinese-US Biotech Collaborations are Revolutionizing Antibody Discovery

VelaVigo’s Bold Move: How Chinese-US Biotech Collaborations are Revolutionizing Antibody Discovery

Frank Dolan April 18, 2025

Eli Lilly's Orforglipron: A Game-Changer in the Fight Against Obesity and Diabetes with Promising Phase 3 Results

Eli Lilly’s Orforglipron: A Game-Changer in the Fight Against Obesity and Diabetes with Promising Phase 3 Results

Frank Dolan April 18, 2025

Blenrep: New Hope for Multiple Myeloma Patients as GSK Secures First Worldwide Approval in the UK

Blenrep: New Hope for Multiple Myeloma Patients as GSK Secures First Worldwide Approval in the UK

Frank Dolan April 17, 2025

Leadership Change at Charm Therapeutics: CEO Laksh Aithani Steps Down as Company Aims for AI-Driven Clinical Trials by 2026

Leadership Change at Charm Therapeutics: CEO Laksh Aithani Steps Down as Company Aims for AI-Driven Clinical Trials by 2026

Frank Dolan April 17, 2025

Bluebird Bio Faces Turbulent Times as Takeover Bid from Ayrmid Falls Flat: What Investors Need to Know

Bluebird Bio Faces Turbulent Times as Takeover Bid from Ayrmid Falls Flat: What Investors Need to Know

Frank Dolan April 17, 2025

Trump's New Drug Pricing Executive Order: A Mixed Bag for the Biopharma Industry

Trump’s New Drug Pricing Executive Order: A Mixed Bag for the Biopharma Industry

Frank Dolan April 16, 2025

GeneDx Acquires Fabric Genomics for $51 Million: A Game-Changer in Genetic Diagnostics

GeneDx Acquires Fabric Genomics for $51 Million: A Game-Changer in Genetic Diagnostics

Frank Dolan April 16, 2025

Johnson & Johnson's 2025 Earnings Outlook: Navigating Tariff Challenges and Investing in U.S. Manufacturing

Johnson & Johnson’s 2025 Earnings Outlook: Navigating Tariff Challenges and Investing in U.S. Manufacturing

Frank Dolan April 16, 2025

Revolutionizing Rare Disease Treatment: How FDA Guidelines are Transforming Orphan Drug Development with AI and Accelerated Approvals

Revolutionizing Rare Disease Treatment: How FDA Guidelines are Transforming Orphan Drug Development with AI and Accelerated Approvals

Frank Dolan April 16, 2025

Unlocking Precision Medicine: How QIAGEN's PGX Platform Enhances Pharmacogenomics with Evidence-Based Data

Unlocking Precision Medicine: How QIAGEN’s PGX Platform Enhances Pharmacogenomics with Evidence-Based Data

Frank Dolan April 16, 2025

Revolutionizing Heart Disease Treatment: Verve Therapeutics Unveils Promising Gene Editing Therapy Verve-102

Revolutionizing Heart Disease Treatment: Verve Therapeutics Unveils Promising Gene Editing Therapy Verve-102

Frank Dolan April 16, 2025

Pharmaceutical Execs Brace for Earnings Turbulence: How Tariffs and Regulatory Changes Could Impact Drug Markets

Pharmaceutical Execs Brace for Earnings Turbulence: How Tariffs and Regulatory Changes Could Impact Drug Markets

Frank Dolan April 16, 2025

Third Harmonic Bio to Liquidate: What This Means for Biotech Investors and Future Therapies

Third Harmonic Bio to Liquidate: What This Means for Biotech Investors and Future Therapies

Frank Dolan April 15, 2025

Pfizer Halts Danuglipron: What This Means for the Future of Obesity Treatments

Pfizer Halts Danuglipron: What This Means for the Future of Obesity Treatments

Frank Dolan April 15, 2025

U.S. Commerce Department Launches Investigation into Pharmaceutical Imports: Are Tariffs on the Horizon?

U.S. Commerce Department Launches Investigation into Pharmaceutical Imports: Are Tariffs on the Horizon?

Frank Dolan April 15, 2025

Bristol Myers Squibb’s Camzyos Faces Major Setback: What It Means for Heart Health and Drug Development

Frank Dolan April 15, 2025

Unraveling the Controversial HHS Layoffs: Legal Challenges and Employee Rights at Stake

Frank Dolan April 15, 2025

Johnson & Johnson Defies Tariff Challenges: Earnings Resilience and Bold Investments for the Future

Johnson & Johnson Defies Tariff Challenges: Earnings Resilience and Bold Investments for the Future

Frank Dolan April 15, 2025

Bipartisan Coalition of 39 Attorneys General Calls for Legislation to Separate Pharmacy Benefit Managers from Pharmacies

Bipartisan Coalition of 39 Attorneys General Calls for Legislation to Separate Pharmacy Benefit Managers from Pharmacies

Frank Dolan April 15, 2025

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

SK and Carlyle Boost Bid for bluebird bio: Major Moves in Biotech Financing and Investments

SK and Carlyle Boost Bid for bluebird bio: Major Moves in Biotech Financing and Investments

Why Experts Are Calling for a Decade-Long Moratorium on Human Germline Editing: Safety, Ethics, and the Future of Gene Therapy

Why Experts Are Calling for a Decade-Long Moratorium on Human Germline Editing: Safety, Ethics, and the Future of Gene Therapy

Breaking Barriers: The Rise of Venture Capital in Women’s Health Amidst Federal Challenges

Breaking Barriers: The Rise of Venture Capital in Women’s Health Amidst Federal Challenges

Email Us

info at arsenal-advisors.com

Headquarters

Cambridge, MA USA